COVID: new antibody treatment could offer up to 18 months’ protection against severe disease

A new treatment could soon help protect people from developing severe COVID. AstraZeneca has just released results from a phase 3 clinical trial – the final stage of testing before a drug is authorised – that suggest its new COVID treatment, AZD7442, is effective at reducing severe disease or death in non-hospitalised COVID patients. THE CONVERSATION